Timothy Hughes, MD, South Australian Health and Medical Research Institute, comments on 2-year randomized trial data showing better outcomes and fewer intolerances for patients taking asciminib versus bosutinib. He also describes the findings of a Canadian trial studying a treatment protocol for patients with molecular relapse re-attempting treatment-free remission, which suggested that a more potent TKI for a shorter timeframe may not be an effective strategy.